Cargando…
Esketamine for treatment resistant depression: a trick of smoke and mirrors?
In March 2019, the US Food and Drug Administration (FDA) approved a nasal spray formulation of esketamine for the treatment of resistant depression in adults. Esketamine is the S-enantiomer of ketamine, an FDA-approved anaesthetic, known to cause dissociation and, occasionally, hallucinations. While...
Autores principales: | Gastaldon, C., Papola, D., Ostuzzi, G., Barbui, C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cambridge University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8061126/ https://www.ncbi.nlm.nih.gov/pubmed/31841104 http://dx.doi.org/10.1017/S2045796019000751 |
Ejemplares similares
-
Esketamine clinical trials: reply to Maju et al.
por: Gastaldon, C., et al.
Publicado: (2020) -
Safety of psychotropic medications in people with COVID-19
por: Ostuzzi, G., et al.
Publicado: (2021) -
Psilocybin: the magic medicine for depression?
por: Corrigan, Amber Elyse, et al.
Publicado: (2021) -
Calling for policy actions to increase access to long-acting antipsychotics in low-income and middle-income countries
por: Ostuzzi, Giovanni, et al.
Publicado: (2022) -
Use of MAOIs in severe treatment-resistant depression: back to the old school
por: Cookey, Jacob
Publicado: (2021)